Loading company…
OncoResponse, Inc. develops monoclonal antibody cancer immunotherapies intended to improve immune responses against tumors.
Founded in 2015 and headquartered in Seattle, US, OncoResponse, Inc. develops cancer immunotherapies, mainly monoclonal antibodies intended to convert cold tumors into hot ones and improve immune responses. Clifford Stocks is CEO. The company has completed nine deals and is at the Series C stage. Its most recent funding round, on May 1, 2023, raised USD 13.91 mn led by RiverVest Ventures.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in